Hurwitz HI - Search Results

1

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ. Loupakis F, et al. Among authors: hurwitz hi. J Natl Cancer Inst. 2015 Feb 24;107(3):dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar. J Natl Cancer Inst. 2015. PMID: 25713148 Free PMC article.

2

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Kabbinavar F, et al. Among authors: hurwitz hi. J Clin Oncol. 2003 Jan 1;21(1):60-5. doi: 10.1200/JCO.2003.10.066. J Clin Oncol. 2003. PMID: 12506171 Clinical Trial.

3

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

Fernando NH, Hurwitz HI. Fernando NH, et al. Among authors: hurwitz hi. Semin Oncol. 2003 Jun;30(3 Suppl 6):39-50. doi: 10.1016/s0093-7754(03)00124-6. Semin Oncol. 2003. PMID: 12802794 Review.

4

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Hurwitz H, et al. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691. N Engl J Med. 2004. PMID: 15175435 Free article. Clinical Trial.

5

Targeted therapy of colorectal cancer: clinical experience with bevacizumab.

Fernando NH, Hurwitz HI. Fernando NH, et al. Among authors: hurwitz hi. Oncologist. 2004;9 Suppl 1:11-8. doi: 10.1634/theoncologist.9-suppl_1-11. Oncologist. 2004. PMID: 15178811 Free article. Review.

6

Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.

Blackwell K, Hurwitz H, Liebérman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Blackwell K, et al. Cancer. 2004 Jul 1;101(1):77-82. doi: 10.1002/cncr.20336. Cancer. 2004. PMID: 15221991 Free article. Clinical Trial.

7

Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

Hurwitz H. Hurwitz H. Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S62-8. doi: 10.3816/ccc.2004.s.010. Clin Colorectal Cancer. 2004. PMID: 15479481 Review.

8

Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.

Collins TS, Hurwitz HI. Collins TS, et al. Among authors: hurwitz hi. Semin Oncol. 2005 Feb;32(1):61-8. doi: 10.1053/j.seminoncol.2004.09.026. Semin Oncol. 2005. PMID: 15726507 Review.

9

New combinations in metastatic colorectal cancer: what are our expectations?

Hurwitz H. Hurwitz H. Oncologist. 2005 May;10(5):320-2. doi: 10.1634/theoncologist.10-5-320. Oncologist. 2005. PMID: 15851788 Free article. Review. No abstract available.

10

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Kabbinavar FF, et al. Among authors: hurwitz hi. J Clin Oncol. 2005 Jun 1;23(16):3706-12. doi: 10.1200/JCO.2005.00.232. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867200 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page